𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Targeting intracellular Aβ42 for Alzheimer's disease drug discovery

✍ Scribed by Michael R. D'Andrea; Daniel H.S. Lee; Hoau-Yan Wang; Robert G. Nagele

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
296 KB
Volume
56
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

β-secretase as a target for the treatmen
β-secretase as a target for the treatment of Alzheimer's disease
✍ Martin Citron 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 1 views

## Abstract Finding inhibitors of the first step of the amyloid cascade, Aβ~42~ generation, is a major goal of Alzheimer's disease drug development. Two target protease activities, β‐and γ‐secretase, were detected more than 10 years ago but progress in this area has been slow because the enzymes we

Cholinergic abnormalities in Alzheimer's
Cholinergic abnormalities in Alzheimer's disease: are there new targets for drug development?
✍ Lisa R. Fodero; David H. Small 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 1 views

## Abstract Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairment and behavioral changes. Cholinesterase inhibitors are currently the drugs of choice for the treatment of AD. However, alternatives to cholinesterase inhibitors such as muscarinic and nicotinic